FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	OVAL
OMB Number:	3235-0287
Estimated average I	burden
houre por roeponeo	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses) 1. Name and Address of Reporting Person * Dupont Jakob				2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]							5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) C/O ATARA BBIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD, SUITE 900				3. Date of Earliest Transaction (Month/Day/Year) 05/14/2020								X Officer (give title below) Other (specify below) EVP, Head of R&D				
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
SOUTH SAN FRANCISCO, CA 94080 (City) (State) (Zip)											nired, Disposed of, or Beneficially Owned					
	1.Title of Security 2. Transaction Date		2. Transaction	2A. Deemed Execution Date, if		3. Transaction		ion 4. (A	4. Securities Acqu (A) or Disposed or (Instr. 3, 4 and 5)		red 5		ecurities Beneficially		orm:	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common S	ltock		05/14/2020				ode A		5,250 A		Price \$ 0	16,250		(I	nstr. 4)	
	port on a sep	parate line for each o	lass of securities bei	пененану	owned dir	ectly of	P	ersons n this fo	rm are r	ot red	quired 1	collection of to respond u I number.				1474 (9-02)
	port on a sep	parate fine for each c	mass of securities ber	nenerany	owned dir	ectry of	P	ersons								1474 (9-02)
1. Title of Derivative Security	2. Conversion or Exercise Price of	3. Transaction	Table II - 3A. Deemed Execution Date, if	Derivat (e.g., pu 4. Transact Code	ive Securit ts, calls, w 5. Nur tion Deriva Securi	ies Acc arrant mber of	quired s, opti f 6. I Exp (Mo	Persons n this for curren l, Dispos	orm are r tly valid ed of, or vertible s reisable ar Date	Denefi Benefi securiti	quired to control cially O ies)	to respond und number. Tweed and Amount orlying	8. Price of	9. Number of Derivative Securities Beneficially	10. Owners Form of Derivat	11. Nati of Indir Benefic ve Owners
1. Title of Derivative Security	2. Conversion or Exercise	3. Transaction Date	Table II - 3A. Deemed Execution Date, if any	Derivat (e.g., pu 4. Transact Code	ive Securit ts, calls, w 5. Nur Deriva Securi Acqui	mber of attive ties red (A) posed of	quired s, opti	Persons In this for curren I, Disposions, con Date Exe	orm are r tly valid ed of, or vertible s reisable ar Date	Denefi Benefi securiti	cially O ies) 7. Title of Unde	to respond under. I number. I n	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	10. Owners Form of Derivat Security Direct (or Indir) (I)	11. Nation of Indirection of Second of Indirection
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table II - 3A. Deemed Execution Date, if any	Derivat (e.g., pu 4. Transact Code	ive Securit ts, calls, w 5. Nur Derive Securi Acqui or Dis (D) (Instr.	mber of thive ties red (A) posed of 3, 4,	quired s, opti f 6. I Exp (Mo	Persons In this for curren I, Disposions, con Date Exe piration I onth/Day	ed of, or vertible strictsable and Date (/Year)	not rec OMB Benefi securiti	cially O ies) 7. Title of Unde	to respond und number. Tweed and Amount orlying	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	10. Owners Form of Derivat Security Direct (or Indir	11. Nation of Indirection of Second of Indirection

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Dupont Jakob C/O ATARA BBIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO, CA 94080			EVP, Head of R&D			

Signatures

/s/ David Tucker, Attorney-in-Fact	05/19/2020
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) 25% of the shares subject to these restricted stock units ("RSUs") vest on May 15, 2021 and 1/16th of the total number shares subject to the RSUs vest on each of the next 12 Quarterly Vesting Dates (as defined below), subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year.
- (2) 25% of the shares subject to the option vest on May 14, 2021 and the remaining shares vest in equal monthly installments over the following 36 months, subject to the reporting person's continuous service.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.